Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 1	2026-07-31		NCT02496663

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	462
Brigham and Women's Hospital	Boston	United States	511
City of Hope Comprehensive Cancer Center	Duarte	United States	263
Dana-Farber Cancer Institute	Boston	United States	626
Duke Cancer Center Cary	Cary	United States	35
Duke University Medical Center	Durham	United States	505
Emory Saint Joseph's Hospital	Atlanta	United States	175
Emory University Hospital Midtown	Atlanta	United States	246
Emory University Hospital/Winship Cancer Institute	Atlanta	United States	299
Massachusetts General Hospital Cancer Center	Boston	United States	178
MedStar Georgetown University Hospital	Washington D.C.	United States	204
Stanford Cancer Institute Palo Alto	Palo Alto	United States	122
UCHealth University of Colorado Hospital	Aurora	United States	172
University of California Davis Comprehensive Cancer Center	Sacramento	United States	299
UPMC Hillman Cancer Center	Pittsburgh	United States	330